Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Moujalled, Diane ^a   James, Janine L ^a,b   Parker, Sarah J ^a,b   Lidgerwood, Grace E ^a,b   Duncan, Clare ^a,b   Meyerowitz, Jodi ^a,b   Nonaka, Takashi ^c   Hasegawa, Masato ^c   Kanninen, Katja M ^d   Grubman, Alexandra ^a,b   Liddell, Jeffrey R ^a,b   Crouch, Peter J ^a,b   White, Anthony R ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HUMAN ANTIGEN R; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE INHIBITOR; RNP K PROTEIN; TAR DNA BINDING PROTEIN; TIAR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; PROTEIN KINASE INHIBITOR; TDP-43 PROTEIN, HUMAN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL GRANULE; CELL STRESS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSOL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PRECLINICAL STUDY; PROTEIN TRANSPORT; TUMOR CELL LINE;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; CYTOSOL; DNA-BINDING PROTEINS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT;

EID: 84879484932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067433     Document Type: Article

References (62)

1. Ferrari R, Kapogiannis D, Huey ED, Momeni P, (2011) FTD and ALS: A Tale of Two Diseases. Curr Alzheimer Res 8: 273-294.
2. Chen-Plotkin AS, Lee VM, Trojanowski JQ, (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 6: 211-220.
3. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133.
4. Barmada SJ, Finkbeiner S, (2010) Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. Rev Neurosci 21: 251-272.
5. Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, et al. (2008) Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci 121: 3778-3785.
6. Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, et al. (2009) Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA 106: 7607-7612.
7. McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, et al. (2011) TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet 20: 1400-1410.
8. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderwyde T, Citro A, et al. (2010) Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 5: e13250.
9. Ito D, Suzuki N, (2011) Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Neurology 77: 1636-1643.
10. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, et al. (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J 29: 2841-2857.
11. Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, et al. (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323: 1208-1211.
12. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323: 1205-1208.
13. Chang JW, Koike T, Iwashima M, (2009) hnRNP-K is a nuclear target of TCR-activated ERK and required for T-cell late activation. Int Immunol 21: 1351-1361.
14. Zhou R, Shanas R, Nelson MA, Bhattacharyya A, Shi J, et al. (2010) Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Int J Cancer 126: 395-404.
15. Buxade M, Parra JL, Rousseau S, Shapiro N, Marquez R, et al. (2005) The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 23: 177-189.
16. Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, et al. (2001) ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol 3: 325-330.
17. Shimada N, Rios I, Moran H, Sayers B, Hubbard K, (2009) p38 MAP kinase-dependent regulation of the expression level and subcellular distribution of heterogeneous nuclear ribonucleoprotein A1 and its involvement in cellular senescence in normal human fibroblasts. RNA Biol 6: 293-304.
18. Guil S, Long JC, Caceres JF, (2006) hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol Cell Biol 26: 5744-5758.
19. Chen LC, Liu HP, Li HP, Hsueh C, Yu JS, et al. (2009) Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells. Oncogene 28: 1904-1915.
20. Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, et al. (2008) Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther 7: 1496-1506.
21. Allemand E, Guil S, Myers M, Moscat J, Caceres JF, et al. (2005) Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc Natl Acad Sci USA 102: 3605-3610.
22. Farooq F, Balabanian S, Liu X, Holcik M, MacKenzie A, (2009) p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR. Hum Mol Genet 18: 4035-4045.
23. Meyerowitz J, Parker SJ, Vella LJ, Ng DCh, Price KA, et al. (2011) C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. Mol Neurodegener 6: 57-64.
24. Parker SJ, Meyerowitz J, James JL, Liddell JR, Crouch PJ, et al. (2012) Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem Int 60: 415-424.
25. Parker SJ, Meyerowitz J, James JL, Liddell JR, Nonaka T, et al. (2012) Inhibition of TDP-43 Accumulation by Bis(thiosemicarbazonato)-Copper Complexes. PLoS One 7: e42277.
26. Ayala V, Granado-Serrano AB, Cacabelos D, Naudi A, Ilieva EV, et al. (2011) Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. Acta Neuropathol 122: 259-270.
27. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, et al. (1992) Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau FEBS Lett. 314: 315-321.
28. Hooper C, Killick R, Lovestone S, (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104: 1433-1439.
29. Nagao M, Watabe K, Hayashi H, Matsubara S, (2011) Glycogen synthase kinase-3 ß localizes to the cytoplasmic inclusions in the spinal motor neurons in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 12: 141-147.
30. Yang R, Zhan M, Nalabothula NR, Yang Q, Indig FE, et al. (2010) Functional significance for a heterogenous ribonucleoprotein A18 signature RNA motif in the 3′-untranslated region of ataxia telangiectasia mutated and Rad3-related (ATR) transcript. J Biol Chem 285: 8887-8893.
31. Nguyen MD, Mushynski WE, Julien JP, (2002) Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ 9: 1294-1306.
32. Schmetsdorf S, Arnold E, Holzer M, Arendt T, Gartner U, (2009) A putative role for cell cycle-related proteins in microtubule-based neuroplasticity. Eur J Neurosci 29: 1096-1107.
33. Cheung ZH, Ip NY, (2012) Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol 22: 169-175.
34. Kabadi SV, Stoica BA, Hanscom M, Loane DJ, Kharebava G, et al. (2012) CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. Neurotherapeutics 9: 405-421.
35. Perlson E, Jeong GB, Ross JL, Dixit R, Wallace KE, et al. (2009) A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration. J Neurosci 29: 9903-9917.
36. Zhu X, Perry G, Smith MA, (2003) Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway. Redox Rep 8: 129-133.
37. Veglianese P, Lo Coco D, Bao Cutrona M, Magnoni R, Pennacchini D, et al. (2006) Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol Cell Neurosci 31: 218-231.
38. Kim EK, Choi EJ, (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405.
39. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, et al. (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 60: 1190-1197.
40. Nonaka T, Arai T, Buratti E, Baralle FE, Akiyama H, et al. (2009) Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. FEBS Lett 583: 394-400.
41. Dreier MR, Bekier ME, Taylor WR, (2011) Regulation of sororin by Cdk1-mediated phosphorylation. J Cell Sci 124: 2976-2987.
42. Kedersha N, Anderson P, (2002) Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochem Soc T 30: 963-969.
43. Lian XJ, Gallouzi IE, (2009) Oxidative stress increases the number of stress granules in senescent cells and triggers a rapid decrease in p21waf1/cip1 translation. J Biol Chem 284: 8877-8887.
44. Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB et al. (2013) CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol doi: 10.1002/ana.23870.
45. Chuang LC, Teixeira LK, Wohlschlegel JA, Henze M, Yates JR, et al. (2009) Phosphorylation of Mcm2 by Cdc7 promotes pre-replication complex assembly during cell-cycle re-entry. Mol Cell 35: 206-216.
46. Ayala YM, Misteli T, Baralle FE, (2008) TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. P Natl Acad Sci USA 105: 3785-3789.
47. Rosania GR, Merlie J, Gray N, Chang YT, Schultz PG, et al. (1999) A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: Biochemical identification using Xenopus egg extracts. Proc Natl Acad Sci USA 96: 4797-4802.
48. Sanchez-Martinez C, Shih C, Faul MM, Zhu GX, Paal M, et al. (2003) Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. Bioorg Med Chem Lett 13: 3835-3839.
49. Crews L, Masliah E, (2010) Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 19: R12-R20.
50. Petit-Paitel A, (2010) GSK-3 beta: a central kinase for neurodegenerative diseases? M S-med Sci 26: 516-521.
51. Wiedau-Pazos M, Wong E, Solomon E, Alarcon M, Geschwind DH, (2009) Wnt-pathway activation during the early stage of neurodegeneration in FTDP-17 mice. Neurobiol Aging 30: 14-21.
52. Palomo V, Perez DI, Gil C, Martinez A, (2011) The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. Curr Med Chem 18: 3028-3034.
53. Hurtado DE, Molina-Porcel L, Carroll JC, MacDonald C, Aboagye AK, et al. (2012) Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease. J Neurosci 32: 7392-7402.
54. Pesiridis GS, Tripathy K, Tanik S, Trojanowski JQ, Lee VM, (2011) A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport. J Biol Chem 286: 18845-18855.
55. Bartoli KM, Bishop DL, Saunders WS, (2011) The role of molecular microtubule motors and the microtubule cytoskeleton in stress granule dynamics. Int J Cell Biol 2011: 939848.
56. Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, et al. (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64: 60-70.
57. Higashi S, Kabuta T, Nagai Y, Tsuchiya Y, Akiyama H et al. (2013) TDP-43 associates with stalled ribosomes and contributes to cell survival during cellular stress. J Neurochem doi: 10.1111/jnc.12194.
58. Habelhah H, Shah K, Huang L, Burlingame AL, Shokat KM, et al. (2001) Identification of new JNK substrate using ATP pocket mutant JNK and a corresponding ATP analogue. J Biol Chem 276: 18090-18095.
59. Freibaum BD, Chitta RK, High AA, Taylor JP, (2010) Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 9: 1104-1120.
60. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, et al. (2005) TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 280: 37572-37584.
61. D'Ambrogio A, Buratti E, Stuani C, Guarnaccia C, Romano M, et al. (2009) Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res 37: 4116-4126.
62. Mori K, Lammich S, Mackenzie IR, Forne I, Zilow S, et al. (2013) hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol 125: 413-423.